Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + nalirifox
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HRS-4642 + NALIRIFOX is an investigational combination therapy being evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC). HRS-4642 is a small molecule inhibitor specifically targeting the KRAS G12D mutation, which is a primary oncogenic driver in nearly 40% of pancreatic cancers. NALIRIFOX is a chemotherapy regimen consisting of liposomal irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and leucovorin. This combination aims to provide a synergistic effect by combining targeted inhibition of the KRAS pathway with broad-spectrum cytotoxic chemotherapy. It is currently being investigated in Phase 2 clinical trials as a neoadjuvant therapy to improve resectability and outcomes in PDAC patients, sometimes in further combination with the PD-L1 inhibitor adebrelimab.
- Other names
- HRS-4642 plus NALIRIFOXHRS4642 plus NALIRIFOXHRS 4642 plus NALIRIFOX
02
Targets
DNAKRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on HRS-4642 + nalirifox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + nalirifox.